Proof of Concept (POC) in Patients With Ischaemic Stroke
A phase 2 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 134 participants.
Also called NCT01808261
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 2
- Enrolled
- 134 participants
- Sponsor
- Registry
-
NCT01808261
-
- Other papers using this trial's data
- Proof-of-Concept Randomized Trial of the Monoclonal Antibody GSK249320 Versus Placebo in Stroke Patients
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Canada, Germany, United Kingdom
- Registry status
- Terminated
Technical summary
Registry record NCT01808261. Randomized; double masking; primary purpose treatment. Start 2013-05-18 (actual); primary completion 2014-07-28 (actual). Results posted on 2017-10-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Proof of Concept (POC) in Patients With Ischaemic Stroke
- Condition
- Cerebrovascular Accident
- Intervention (Drug)
- GSK249320 100/mg
- Intervention (Drug)
- Placebo
- Lead sponsor
- GlaxoSmithKline
Record details
- Record id
cardio:ct-nct01808261- Content hash
b5a9dd74158c20f65497d86e9a52c4c94baa93e7bdfe7d68eaf66f9d58f9571b